Health Trials

Effects of Microbiological and Immunological Factors on the Lower Urinary Tract

ConditionsAsymptomatic Bacteriuria in Subjects Not Requiring Assisted Bladder EmptyingAsymptomatic Bacteriuria in Subjects Relying on Some Type of CatheterRecurrent Non-catheter Associated UTIsAcute Catheter-associated UTI (CAUTI)Recurrent Catheter-associated UTI (CAUTI)Chronic Pelvic PainNon-neurogenic Overactive Bladder Syndrome / LUT SymptomsNon-muscle-invasive Bladder Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Zurich

About this trial

Millions of patients of all ages suffer worldwide from diverse urinary pathologies, such as lower urinary tract (LUT) dysfunction, bladder pain syndrome, urinary tract infections (UTIs), or bladder cancer. The research project investigates the interplay between the bladder and the microbiome. The goal is to evaluate the association of microbiological and immunological factors with lower urinary tract health in humans.

Eligibility criteria

Qualifiers

Women and men aged ≥ 18 years old

Able to give informed consent for participation in the study

Willing to adhere to the study protocol for the whole trial period

Willing to undergo repetitive in-and-out single catheterization Specific inclusion criteria for the different study arms Arm I: Healthy controls Arm II: Asymptomatic bacteriuria in subjects not requiring assisted bladder emptying Arm III: Asymptomatic bacteriuria in subjects relying on some type of catheter for bladder emptying Arm IV: Acute non-catheter associated UTIs Arm V: Recurrent non-catheter associated UTIs Arm VI: Acute catheter-associated UTI Arm VII: Recurrent catheter-associated UTI Arm VIII: Chronic pelvic pain Arm IX: Non-neurogenic overactive bladder syndrome Arm X: Non-muscle-invasive bladder cancer

Disqualifiers

Current antibiotic treatment or antibiotic treatment within the last 21 days (except for study arms IV-VII)

UTI secondary to diagnosed treatable pathologies (i.e., bladder stones, enterovesical fistula etc.) and requiring specific therapy Current therapies for preventing UTIs (e.g., urine acidification, phytotherapy) or such therapies within the last 21 days (except for study arms IV-VII)

Deterioration of the upper urinary tract requiring medical intervention

Immunomodulatory therapies (apart from routine vaccination)

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

800 Participants
are grouped into 10 trial groups

10

Trial groups

See each trial group below.

Sponsors and collaborators

University of Zurich

Lead sponsor

Kessler Group

Collaborator

Rätsch Group

Collaborator

Slack Group

Collaborator

Boyman Group

Collaborator

Sunagawa Group

Collaborator

Zamboni Group

Collaborator

Loessner Group

Collaborator

McKinney Group

Collaborator

Nexus

Collaborator

Research Group Dirk Bumann

Collaborator

Research Group Christoph Dehio

Collaborator

Source ClinicalTrials.gov